# Streamlining Multi-Region Submissions: Orchestrating MDR, FDA, and EU AI Act Documentation for AI-Enabled Devices

November 20, 2025

,

11:00 am

EST

60

mins

Recorded on

November 20, 2025

60

mins

Bringing AI-enabled medical devices to market means meeting overlapping FDA, EU MDR, and EU AI Act requirements. The AI Act classifies most medical AI as high-risk, requiring conformity assessment, data governance, transparency, and human oversight alongside MDR’s clinical evaluation and post-market surveillance. In the U.S., the FDA expects full traceability under design control, risk management per ISO 14971, and documented verification and validation of software, algorithms, and data changes across the lifecycle.

## What you'll learn

- Generate compliant MDR, FDA, and EU AI Act documentation automatically from shared data
- Meet EU AI Act expectations for transparency, human oversight, and data governance in high-risk AI systems
- Link shared development artifacts to MDR clinical evaluation and FDA design control evidence without duplication

‍

## Who should attend

Register to

watch

attend

Conversion Page

Landing Page

utm\_campaign

utm\_content

utm\_medium

utm\_source

utm\_term

Asset Name

LinkedIn Asset Name

Get informed of webinars like this one.

This browser does not support HTML video.

Click for sound

Click for sound

### Clips from this Webinar

## Speakers

### Jenn Dixon

Director of AI Quality & Regulatory Strategy

[Ketryx](https://www.ketryx.com/learn/webinars/register/streamlining-multi-region-submissions#)

Formerly

### Carlton O'Neal

Product Manager

[Ketryx](https://www.ketryx.com/learn/webinars/register/streamlining-multi-region-submissions#)

Formerly

## Interested?

[Register now](https://www.ketryx.com/learn/webinars/register/streamlining-multi-region-submissions#register)